BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $111.00

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lifted by Barclays from $105.00 to $111.00 in a report issued on Monday,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

Other equities analysts have also recently issued research reports about the stock. Sanford C. Bernstein lowered their target price on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 5th. UBS Group reaffirmed a “neutral” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, July 14th. Citigroup increased their price objective on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a “buy” rating in a report on Thursday, July 16th. HC Wainwright raised their price objective on shares of BioMarin Pharmaceutical from $50.00 to $60.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Finally, Canaccord Genuity Group boosted their target price on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a “buy” rating in a report on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average target price of $88.83.

BioMarin Pharmaceutical Price Performance

Shares of BMRN opened at $69.33 on Monday. The firm has a market capitalization of $13.42 billion, a price-to-earnings ratio of 187.38, a price-to-earnings-growth ratio of 0.48 and a beta of 0.24. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. BioMarin Pharmaceutical has a one year low of $49.26 and a one year high of $70.98. The stock’s fifty day moving average is $60.21 and its 200-day moving average is $57.74.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. The business had revenue of $989.71 million for the quarter, compared to analysts’ expectations of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The company’s revenue was up 20.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities analysts anticipate that BioMarin Pharmaceutical will post 4.11 EPS for the current year.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Several large investors have recently made changes to their positions in the business. Thornburg Investment Management Inc. grew its stake in shares of BioMarin Pharmaceutical by 305.9% in the 2nd quarter. Thornburg Investment Management Inc. now owns 43,061 shares of the biotechnology company’s stock worth $2,464,000 after purchasing an additional 32,453 shares during the last quarter. Greenwood Capital Associates LLC bought a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter worth approximately $320,000. Van ECK Associates Corp lifted its stake in BioMarin Pharmaceutical by 68.8% during the second quarter. Van ECK Associates Corp now owns 307,103 shares of the biotechnology company’s stock valued at $17,572,000 after purchasing an additional 125,221 shares during the last quarter. Hsbc Holdings PLC lifted its stake in BioMarin Pharmaceutical by 107.5% during the second quarter. Hsbc Holdings PLC now owns 307,543 shares of the biotechnology company’s stock valued at $17,640,000 after purchasing an additional 159,361 shares during the last quarter. Finally, Palo Alto Investors LP bought a new stake in BioMarin Pharmaceutical during the second quarter worth approximately $39,068,500,000. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, with up to $215 million in milestone payments. The transaction gives BioMarin rights to ALE1, an oral therapy being developed for hypophosphatasia (HPP), a rare genetic bone disorder. The potential to offer a first oral treatment could address a significant unmet need and expand BioMarin’s presence in rare skeletal diseases. CNBC article
• Positive Sentiment: Investors and analysts see strategic and longer-term growth potential from adding ALE1 to BioMarin’s pipeline. Wedbush said the acquisition strengthens the company’s outlook, while BMO Capital Markets initiated coverage with an Outperform rating and a $98 price target, implying substantial upside from the referenced price. Barclays and Piper Sandler also issued bullish forecasts. Wedbush article
• Neutral Sentiment: The acquisition broadens BioMarin’s rare-disease portfolio, but ALE1 is still in early clinical trials. Its commercial value depends on successful development, regulatory approval and achievement of milestones, making the program a longer-term rather than immediate revenue driver. Alesta will also spin out its other assets before closing. BioMarin announcement
• Negative Sentiment: HC Wainwright lowered its price target from $60 to $59 and maintained a Neutral rating, while another analyst cut its target to $59. These targets suggest some investors believe the stock’s recent rise has outpaced near-term fundamentals and that execution and valuation risks remain. Analyst coverage

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.